ArticleCureus2025
Real-World Outcomes of Antiretroviral Therapy in People Living With HIV in Saudi Arabia: A Three-Year Observational Cohort Study From a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment adherence is an essential determinant in the management of HIV. In an observational cohort study in Saudi Arabia, the clinical outcomes of antiretroviral therapy (ART) in terms of viral suppression and treatment adherence were evaluated among people living with HIV.
methodIn an open, single-center, observational cohort study, 700 patients were enrolled and followed for three years, either in person or virtually. The study aimed to help patients transition to the U = U (undetectable = untransmittable) category as per the Preventive Access Campaign. The viral load was estimated every three months. Treatment adherence was calculated based on the number of missed doses by the patients.
resultsIn this observational cohort study, 700 patients received ART treatment of various types. The patients presented varying disease durations ranging from one to 20 years. The triple drug combination comprising bictegravir/emtricitabine/tenofovir (B/F/TAF) was the most prescribed ART. At the end of 36 months, 616 patients reached the U = U category. A significant reduction in viral load was observed at 12, 24, and 36 months from baseline (p < 0.05; 95% confidence interval (CI)). All patients tolerated the ART, and there were no treatment discontinuations due to side effects. The average treatment adherence was more than 95% across all the cohorts. An increase in viral load was observed with missing doses; however, the newer ARTs effectively controlled viral load during the ART-reduced adherence.
conclusionsHIV is treatable, and with effective treatment, patients can achieve "untransmittable" status. This study demonstrates the effectiveness of the newer ARTs in HIV management in Saudi Arabia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.